Primary Adrenal Insufficiency during Immune Checkpoint Inhibitor Treatment: Case Reports and Review of the Literature

被引：15

作者：

Salinas, Carlos ^{[1
]}

Renner, Alex ^{[1
]}

Rojas, Carlos ^{[1
,2
]}

Samtani, Suraj ^{[1
]}

Burotto, Mauricio ^{[1
,2
]}

机构：

[1] Med Oncol Serv Bradford Hill, Santiago, Chile

[2] Clin Univ Andes, Med Oncol Serv, Las Condes, Chile

来源：

CASE REPORTS IN ONCOLOGY | 2020年 / 13卷 / 02期

关键词：

Ipilimumab; Nivolumab; Primary adrenal insufficiency; Immune-related adverse events; NIVOLUMAB PLUS IPILIMUMAB; OPEN-LABEL; MULTICENTER;

D O I：

10.1159/000507652

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

As the indications and clinical use of immune checkpoint inhibitors increase, it is expected that we will face some of their less frequently reported complications. Primary adrenal insufficiency is one of them, and given its unspecific symptoms and potentially serious consequences, it is important to have a high degree of clinical suspicion. We present 3 cases and a review of the literature concerning its main clinical characteristics, diagnostics, and management.

引用

页码：621 / 626

页数：6

共 50 条

[1] Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis
Grouthier, Virginie
Lebrun-Vignes, Benedicte
Moey, Melissa
Johnson, Douglas B.
Moslehi, Javio J.
Salem, Joe-Elie
Bachelot, Anne
ONCOLOGIST, 2020, 25 (08) : 696 - 701
[2] Routine Screening for Central and Primary Adrenal Insufficiency during Immune-Checkpoint Inhibitor Therapy: An Endocrinology Perspective for Oncologists
Druce, Irena
Tawagi, Karine
Shaw, Julie L., V
Ibrahim, Andrea
Lochnan, Heather
Ong, Michael
CURRENT ONCOLOGY, 2022, 29 (07) : 4665 - 4677
[3] Graves' Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review)
Peiffert, Mathilde
Cugnet-Anceau, Christine
Dalle, Stephane
Chikh, Karim
Assaad, Souad
Disse, Emmanuel
Raverot, Gerald
Borson-Chazot, Francoise
Abeillon-du Payrat, Juliette
CANCERS, 2021, 13 (08)
[4] Immune checkpoint inhibitor therapy for primary neuroendocrine carcinoma of the gallbladder: A case report and literature review
Li, Chao
Lv, Pan
Liu, Yanyan
Yin, Maohui
Li, Hao
MEDICINE, 2024, 103 (43)
[5] Management of immune checkpoint inhibitor-related adverse events: A review of case reports
Si, Xiaoyan
Song, Peng
Ni, Jun
Di, Mingyi
He, Chunxia
Zhang, Li
Liu, Xiaowei
Li, Yue
Wang, Hanping
Guo, Xiaoxiao
Zhou, Jiaxin
Duan, Lian
Yang, Xu
Wang, Mengzhao
Zhang, Li
THORACIC CANCER, 2020, 11 (03) : 498 - 504
[6] Vedolizumab in the treatment of immune checkpoint inhibitor-induced colitis: Two case reports
Zhang, Zhe
Zheng, Chang-Qing
WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (29) : 10550 - 10558
[7] Immune checkpoint inhibitor-associated new-onset primary adrenal insufficiency: a retrospective analysis using the FAERS
Lu, D.
Yao, J.
Yuan, G.
Gao, Y.
Zhang, J.
Guo, X.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2022, 45 (11) : 2131 - 2137
[8] Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review
Okura, Naoko
Asano, Mai
Uchino, Junji
Morimoto, Yoshie
Iwasaku, Masahiro
Kaneko, Yoshiko
Yamada, Tadaaki
Fukui, Michiaki
Takayama, Koichi
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (07) : 1 - 12
[9] Primary Adrenal Insufficiency and Acute Cardiomyopathy in a Patient With Colorectal Cancer Treated With Dual Immune Checkpoint Inhibitors
Kojadinovic, Arsenije
Mundi, Prabhjot S.
CLINICAL COLORECTAL CANCER, 2021, 20 (04) : E249 - E252
[10] Immune checkpoint inhibitor-related adrenal hypofunction and Psoriasisby induced by tislelizumab: A case report and review of literature
Deng, Yisi
Huang, Manling
Deng, Runpei
Wang, Jun
MEDICINE, 2024, 103 (12) : E37562

← 1 2 3 4 5 →